JP2015510125A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510125A5
JP2015510125A5 JP2014556742A JP2014556742A JP2015510125A5 JP 2015510125 A5 JP2015510125 A5 JP 2015510125A5 JP 2014556742 A JP2014556742 A JP 2014556742A JP 2014556742 A JP2014556742 A JP 2014556742A JP 2015510125 A5 JP2015510125 A5 JP 2015510125A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
sample
expression
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014556742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510125A (ja
JP6602012B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/025392 external-priority patent/WO2013119990A2/en
Publication of JP2015510125A publication Critical patent/JP2015510125A/ja
Publication of JP2015510125A5 publication Critical patent/JP2015510125A5/ja
Application granted granted Critical
Publication of JP6602012B2 publication Critical patent/JP6602012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014556742A 2012-02-10 2013-02-08 Ｃｄ３０＋癌の検出と治療 Active JP6602012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261597547P 2012-02-10 2012-02-10
US61/597,547 2012-02-10
PCT/US2013/025392 WO2013119990A2 (en) 2012-02-10 2013-02-08 Detection and treatment of cd30+ cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018046117A Division JP6744885B2 (ja) 2012-02-10 2018-03-14 Ｃｄ３０＋癌の検出と治療

Publications (3)

Publication Number Publication Date
JP2015510125A JP2015510125A (ja) 2015-04-02
JP2015510125A5 true JP2015510125A5 (enExample) 2016-03-31
JP6602012B2 JP6602012B2 (ja) 2019-11-06

Family

ID=48948166

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014556742A Active JP6602012B2 (ja) 2012-02-10 2013-02-08 Ｃｄ３０＋癌の検出と治療
JP2018046117A Active JP6744885B2 (ja) 2012-02-10 2018-03-14 Ｃｄ３０＋癌の検出と治療
JP2020059264A Active JP7026158B2 (ja) 2012-02-10 2020-03-30 Ｃｄ３０＋癌の検出と治療
JP2022020085A Pending JP2022070958A (ja) 2012-02-10 2022-02-14 Ｃｄ３０＋癌の検出と治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018046117A Active JP6744885B2 (ja) 2012-02-10 2018-03-14 Ｃｄ３０＋癌の検出と治療
JP2020059264A Active JP7026158B2 (ja) 2012-02-10 2020-03-30 Ｃｄ３０＋癌の検出と治療
JP2022020085A Pending JP2022070958A (ja) 2012-02-10 2022-02-14 Ｃｄ３０＋癌の検出と治療

Country Status (8)

Country Link
US (3) US10444241B2 (enExample)
EP (2) EP2812702B1 (enExample)
JP (4) JP6602012B2 (enExample)
CN (2) CN104254778A (enExample)
AU (1) AU2013216863B2 (enExample)
CA (1) CA2864092C (enExample)
ES (1) ES2725569T3 (enExample)
WO (1) WO2013119990A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2812702B1 (en) 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
AU2016347516A1 (en) * 2015-10-30 2018-05-10 Glaxosmithkline Intellectual Property Development Limited Prognostic method

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2734287C2 (de) 1977-07-29 1983-02-10 Manfred 7250 Leonberg Luik Gerät zum Reinigen von Gegenständen, insbesondere Zahnprothesen
EP0000877B1 (de) 1977-08-31 1983-05-18 Grisebach, Hans-Theodor Manipulator zum Positionieren von Werkstücken oder anderen Lasten
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
WO1992019973A1 (en) 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2131528C (en) 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993024135A1 (en) * 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
KR100890088B1 (ko) * 2001-02-12 2009-03-24 메다렉스, 인코포레이티드 Ｆｃ 알파 수용체（ＣＤ８９）에 대한 인간 모노클로날 항체
CA2446806A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
WO2003000286A1 (en) * 2001-06-22 2003-01-03 Daiichi Suntory Pharma Co., Ltd. Remedies for eosinophilic diseases
WO2003059282A2 (en) * 2002-01-09 2003-07-24 Medarex, Inc. Human monoclonal antibodies against cd30
AU2003239248A1 (en) * 2002-06-07 2003-12-22 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
KR20070083899A (ko) * 2004-10-01 2007-08-24 메다렉스, 인코포레이티드 Ｃｄ30 양성 림프종의 치료 방법
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
AU2005316844A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
BRPI0607203A2 (pt) * 2005-02-18 2009-08-25 Medarex Inc anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
JPWO2008041594A1 (ja) * 2006-09-26 2010-02-04 オリンパス株式会社 抗体医薬感受性検査方法
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
AU2008310908B2 (en) * 2007-10-12 2014-01-09 Seagen Inc. Combination therapy with antibody-drug conjugates
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
DK2842575T3 (da) 2008-03-18 2017-11-27 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
CA3150199C (en) 2009-01-09 2025-07-22 Seagen Inc WEEKLY DOSING REGIMEN FOR ANTI-CD30 ANTIBODY CONJUGATIONS VC-PAB-MMAE - MEDICINE
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
IL300733B1 (en) * 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
EP2812702B1 (en) 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers

Similar Documents

Publication Publication Date Title
Stecca et al. Recent advances in the management of penile cancer: a contemporary review of the literature
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
Zhang et al. The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer
BR112019001384A2 (pt) teste de combinação para câncer colorretal
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
JP2018155752A5 (enExample)
BR112019006404A2 (pt) métodos para diagnóstico e tratamento de câncer de próstata metastático resistente à castração sensível ou resistente a acetato de abiraterona-glicocorticoide
Huang et al. Current clinical uses of the biomarkers for hepatocellular carcinoma
JP2015510125A5 (enExample)
Dai et al. Comparison of liver resection and transplantation for Child-pugh A cirrhotic patient with very early hepatocellular carcinoma and portal hypertension
Alkotyfan et al. Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharnyx
de Almeida et al. Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma
WO2012092529A3 (en) Protein biomarkers of recurrent breast cancer
Campos Novel Mutations in Endometriosis-Associated Ovarian Cancers
Jeng et al. Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma
Clarke et al. Long term risk prediction of p16/Ki-67 dual stain in triage of HPV-positive women
邱至謙 et al. Severe Hypokalemia and Rhabdomyolysis Associated with Conn's Syndrome: Clinical Approach to Aldosterone-Related Kaliuresis
Dvorak et al. Evaluation of BRAF (V600E) mutation by immunohistochemical staining with anti-BRAF V600E (VE1) antibody: A comparison with Sanger sequencing.
Lestari et al. miR-21, miR-29c, and miR-155 as Biomarker to Develop Minimal Invasive Diagnostic in Hepatocellular Carcinoma Patient
Horn et al. 3-tiered Molecular Classification of Squamous Cell Vulvar Cancer: Matched-pair analysis: pre-surgical biopsy versus radical vulvectomy from the same patient: 961
Zhang et al. Enhancement of anti-melanoma effect of BRAF and MEK inhibition by metformin
Rahman et al. Neutrophil to lympho-cyte ratio as predictive marker of recurrence of HCC after radiofrequency ablation
Arvin-Berod et al. Accuracy of ureteroscopic biopsy for upper tract urothelial carcinoma: A retrospective study comparing biopsy and final pathologic results